English | Español

Technology/Innovation
+ Technology/Innovation
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
+ Technology/Innovation
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
+ Technology/Innovation
Patient Daily | May 7, 2023

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
+ Technology/Innovation
Patient Daily | May 7, 2023

Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
+ Technology/Innovation
Patient Daily Report | May 5, 2023

Eli Lilly on new Alzheimer's drug: 'We are extremely pleased that donanemab yielded positive clinical results'
+ Technology/Innovation
Patient Daily | May 4, 2023

Device Talks Boston 2023
+ Technology/Innovation
Patient Daily | May 4, 2023

RELIAS ANNOUNCES UPDATES TO LEARNER MOBILE APP
+ Technology/Innovation
Patient Daily | May 4, 2023

Completion of Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX with or without Nivolumab as First-line Treatment of Gastric/Gastro-esophageal Junction Cancer Patients

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes